CMS monoclonal antibody injection "MG-K10" listing application accepted

AASTOCKS
2025.10.30 13:12

CMS (00867.HK) announced that its subsidiary, Demei Pharmaceutical, along with its affiliates, has obtained the joint development rights and exclusive commercialization rights for the Class 1 new drug anti-IL-4Rα MG-K10 humanized monoclonal antibody injection (generic name: Kemeiqibai monoclonal antibody injection, "MG-K10"). The application for marketing authorization in China has been accepted by the National Medical Products Administration of China.

"MG-K10" is intended for the treatment of moderate to severe atopic dermatitis in adults who have inadequate control with topical medications or for whom topical treatments are not suitable

Source: AASTOCKS The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer